Bell Potter Healthcare conference presentation
Released
Released
Announcement PDF
Lead nasal
spray portfolio
Bell Potter Healthcare Conference
November 2025
1
Important Notice & Disclaimer
2
‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd
(Company or LTP) to provide general information about the Company. The information in this
document is in summary form and should not be relied upon as a complete and accurate
representation of any matters that a reader should consider in evaluating the Company. While
management has taken every effort to ensure the accuracy of the material in this presentation,
the Company have not verified the accuracy or completeness of the material contained in this
presentation.
‣ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or
purchase LTP securities. This presentation is not exhaustive and does not contain all of the
information a potential investor, or their professional advisers would require, and it does NOT
constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001
(Cth), and has not been, and will not be, lodged with the Australian Securities and Investments
Commission or any other regulatory authority. This presentation should not be distributed,
transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or
viewing of this document would be unlawful under the securities or other laws of that or any
other jurisdiction. In particular, this presentation may not be released to US wire services or
distributed publicly in the United States. See the section of this presentation captioned
“International Offer Jurisdictions” for more information. This presentation does not constitute an
offer to sell, or a solicitation of an offer to buy any securities in any jurisdiction. Any failure to
comply with such restrictions could constitute a violation of applicable securities laws.
‣ Not financial product advice: You should not act and should refrain from acting in reliance on
this presentation. Nothing contained in this presentation constitutes investment, legal, tax or
other advice. This presentation does not take into account the individual investment objectives,
financial situation and particular needs of potential investors. Before making a decision to invest
in the Company at any time, you should conduct, with the assistance of your broker or other
financial or professional adviser, your own investigation in light of your particular investment
needs, objectives and financial circumstances and perform your own analysis of the Company
before making any investment decision.
‣ Forward looking statements: This presentation contains forward-looking information about the
Company and its operations. In certain cases, forward-looking information may be identified by
such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”,
"expects", "may", “intend”, "shall", "will", or "would". These statements are based on information
currently available to the Company and the Company provides no assurance that actual results
will meet management's expectations. Forward-looking statements are subject to risk factors
associated with the Company’s business, many of which are beyond the control of the Company.
It is believed that the expectations reflected in these statements are reasonable but they may be
affected by a variety of variables and changes in underlying assumptions which could cause
actual results or trends to differ materially from those expressed or implied in such statements.
There can be no assurance that actual outcomes will not differ materially from these
statements.
‣ Disclaimer: No representation or warranty, express or implied, is made by the Company that the
material contained in this presentation will be achieved or proved correct. Except for statutory
liability which cannot be excluded, the Company, its directors, officers, and employees expressly
disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material
contained in this presentation and excludes all liability whatsoever (including in negligence) for
any loss or damage which may be suffered by any person as a consequence of any information
in this presentation or any effort or omission therefrom. The Company will not update or keep
current the information contained in this presentation or to correct any inaccuracy or omission
which may become apparent, or to furnish any person with any further information. Any
opinions expressed in the presentation are subject to change without notice.
‣ LTR Pharma Limited ACN 644 924 569
Bell Potter HCC | November 2025
Executive
Summary
4
LTR Pharma
Late-Stage Pharmaceutical
Platform with Validated Early
Market Access
Rapidly commercialising SPONTAN® and ROXUS®
First-in-class rapid, on-demand nasal spray treatments
for Erectile Dysfunction (ED)
SPONTAN
Now available under TGA's Special Access Scheme (SAS), generating real-world
evidence to support full commercial rollout and upcoming FDA Phase II clinical
study (Q1 2026)
Clinically validated platform
Demonstrating rapid onset and consistency – supporting expansion into
multiple indications
ROXUS
Targeted for H1 2026 launch in the U.S., addressing the personalised
medicine market for ED
Bell Potter HCC | November 2025
Growing pipeline
Additional SPONTAN® variants under development for ED and new
indications, price points, including OROFLOW® for oesophageal motility
disorders
Investment Highlights
5
LTR Pharma positioned in a clear gap in the market
Compelling pivotal
pharmacokinetic
study data
‣ 5x faster absorption than
oral tablets
Multiple path
to market
‣ SPONTAN® active
in Australia via SAS
‣ ROXUS® targeting US
personalised medicine
H1 CY2026
‣ Regulatory approvals
expanding market access
Blockbuster
market with issues
‣ Existing PDE5 inhibitors
have a high discontinuation
rate due to poor efficacy
and side effects
Blue chip
partners
‣ Aptar Pharma: Strategic
Co-development partner -
Nasdaq listed;
‣ Mayne Pharma:
Commercial manufacturing
partner (CMO) - ASX listed
‣ Symbion – Australian
distributor, owned by ASX
listed EBOS Group
Multiple upcoming
milestones
‣ SPONTAN Phase II PK
Study
‣ ROXUS launch H1 CY 2026
‣ ROXUS® development
completed
‣ Growing Online Prescribing
‣ SPONTAN Animal Tox Study
‣ Published data
‣ Partnership discussions
‣ OROFLOW®
development for OMD
Bell Potter HCC | November 2025
Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
Understanding
the Market Need
8
A significant healthcare
challenge affecting
relationships and
quality of life
Physical causes
‣ Heart health
‣ Hormone balance
‣ Prostate Cancer
‣ Diabetes
‣ Medical treatments
‣ Hair loss
‣ Weight loss
‣ Antidepressants
Psychological Impact
‣ Relationship problems
‣ Mental wellbeing
‣ Day to day stress
60%
50%
Growing prevalence with
age impacts quality of life
Of men over
45 experience ED2
Stop purchasing
PDE5 tablets1
1) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation,"
Journal of Sexual Medicine, May 2012. 2) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
Bell Potter HCC | November 2025
In Key Markets
9
As risk factors become more prevalent, so does ED
Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
~30m ~33m ~150m
60.7%
of males 45y/o+
USA
EU
China
Aus
Bell Potter HCC | November 2025
First and only PDE5 nasal spray, available now in Australia under TGA early access.
Product Main
Brand(s)
Time before sexual
activity for dose
Approval
Date (US)
Generic
availability
Sildenafil Viagra 1 hour+ 1998 Yes
Tadalafil Cialis 1 hour+ 2003 Yes
Varendafil
Levitra,
Staxyn
1 hour+ 2003 Yes
Avanafil Stendra 30 minutes+ 2012 No
Current Treatments
11
Oral Phosphodiesterase-5 (PDE5)
inhibitors are first-line treatments
Issues with oral
PDE5 inhibitors
Oral PDE5 inhibitors & SPONTAN® Nasal Spray
Does not work
for 30-35% of patients
Long response time of
1 hour + affects spontaneity
Adverse reactions
in up to 35% of patients
= High discontinuation rate
Bell Potter HCC | November 2025
Nasal Administration
12
Delivery mechanism can solve many
of issues facing PDE5 inhibitors
Advantages vs oral administration
More rapid
onset of action
Higher rate
of absorption
Lower adverse
reactions
Less active
pharmaceutical
ingredients required
Less drug degradation
due to bypassing the
digestive system
Bell Potter HCC | November 2025
Parameter
SPONTAN®
Pivotal Pharmacokinetic Study
14
‣ SPONTAN® nasal spray achieved rapid absorption and
faster onset of action compared to oral PDE5 inhibitors.
‣ SPONTAN® delivered similar bioavailability (Cmax) at half
the dose of oral PDE5 inhibitors.
‣ Significantly faster (Tmax) with SPONTAN® in as little
as 9 min (avg. 12 min) vs oral (56 min) - longest 2.5 hours.
‣ Confirmed safety and tolerability profile of SPONTAN® vs
oral dosing PDE5 Inhibitors.
‣ SPONTAN® demonstrated more consistent dosing
than oral PDE5 Inhibitors.
‣ Data to be used in regulatory filings in US, Australia
and other key markets.
Rapid onset effect, consistent delivery
and improved safety profile
‣ Cmax (ng/ml).
(5mg)
Vardenafil
(10mg) oral
‣ 13.0 ‣ 16.7
‣ Adverse Events ‣ 0 ‣ 1
‣ Tmax (min) ‣ 12 (range 9-15) 56 (Longest 150)
Bell Potter HCC | November 2025
In-Market NOW
16
Early adoption validates
platform scalability
across multiple channels
Commercial Platform Active: Growing Prescriber Network
‣ RHC – experts in treating ED and early adopters of SPONTAN
‣ Online bookings, consults, men’s health education, telehealth
solutions and prescribing SPONTAN on
‣ https://rshealth.com.au and https://makehardeasy.com.au
1. JV with Restorative
Health Clinic (RHC)
‣ Australia’s largest men’s health pharmacy clinic network
‣ Significant referral network of GPs, urologists, and sexual health clinics
‣ Online telehealth appointment / SPONTAN Nasal Spray prescribing on
‣ https://menshealthdownunder.com.au
2. Men’s Health
Downunder (MHDU)
‣ Specialist GP Men’s Health Services
‣ Online telehealth appointments on
‣ https://kangaroopointmedicalcentre.com.au
‣ Symbion pharmacy network of over 3900 pharmacies
‣ Terrey White Chemmart nationwide
4. Pharmacy Networks
3. Kangaroo Point
Bell Potter HCC | November 2025
US Commercialisation
17
SPONTAN® > Broad Market Expansion
‣ FDA 505(b)(2) pathway
‣ FDA Approval enables broad market expansion
‣ Benefits from ROXUS commercialisation in the market
‣ Phase II PK study, enrolling Q1 2026 and then progressing to Phase III Safety and Efficacy study
ROXUS > Early Market Entry via Personalised Medicine
‣ ROXUS to be available via 503(a) personalised medicine pathway
‣ Market entry with 1st sales targeted for H1 CY2026
‣ Focus on urology/men’s health prescribers and telehealth
‣ Builds US brand, relationships, and real-world use case data
‣ Accesses $6B+ US personalised healthcare market (2025), independent of SPONTAN FDA timeline
Multiple Active Routes to Market
Bell Potter HCC | November 2025
Q1 2026 H1 2026 2026
Phase II Clinical Study enrolment 1st US Sales Published data
ROXUS Development Completed Phase II completion and data read out OROFLOW development
Human factor study completion Partnerships discussions
Animal Toxicology Program
2025-2026
Key Milestones
Calendar Year
20
Bell Potter HCC | November 2025
Growing Pipeline of Novel Nasal Spray Treatments
21
Indication/
Program
Pre-clinical Proof of
Concept
Phase 1
(PK study)
Phase 2
(PK study)
Phase 3
Erectile Dysfunction (ED)
/ TGA early access
/ FDA 503(a)
Personalised
Medicine
/ FDA 505(b)(2)
Expanding Pipeline & Strategic Investments
OROFLOW
omega-3
Available now
Validated Platform Supporting Multiple Indications
Platform scalability demonstrated through successful clinical validation
Current
Completed Completed Completed
Completed Current
Current Planned
Launch in US via personalised healthcare market
Current Planned
Bell Potter HCC | November 2025
Bell Potter HCC | November 2025
Corporate Structure
ASX Code LTP
Shares on issue 181.61M
Market Capitalisation A$79.91M
Cash and cash equivalents (30 June 2025) A$31.84M
Top 20 shareholder percentage 43.22%
As of 7 November 2025
investors@ltrpharma.com
www.ltrpharma.com
Authorised for release by the Board of Directors
Contact
Share your feedback
Discover